MedTrace Logo

The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

NCT01906788 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-07-24

No results posted yet for this study

Summary

The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected individuals to less than one week after initiation of treatment"

Conditions

  • Malaria Transmission

Interventions

DRUG

Artemether Lumefantrine

DRUG

Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0

DRUG

Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2

Sponsors & Collaborators

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • Ifakara Health Institute

    collaborator OTHER

  • Kilimanjaro Clinical Research Institute

    lead OTHER

Principal Investigators

  • Seif Shekalaghe, MD, PhD · Kilimanjaro Clinical Research Institute and Ifakara Health Institute

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01906788 on ClinicalTrials.gov